Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 8/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27391201 | 0.85 | ATM (0.37) | HSD17B10NPC1RAB9AOPRD1OPRM1 | |
| SCHEMBL24799219 | 0.82 | NPC1 (0.35) | HSD17B10NPC1RAB9AOPRD1KDM4E | |
| SCHEMBL173508 | 0.81 | HSD17B10 (0.64) | HSD17B10KDM4EALDH1A1SLC6A9 | |
| Tetraxetan SCHEMBL2017956 | 0.81 | HSD17B10 (0.64) | HSD17B10KDM4EALDH1A1SLC6A9 | |
| SCHEMBL3503521 | 0.81 | HSD17B10 (0.64) | HSD17B10KDM4EALDH1A1SLC6A9 | |
| Tetraxetan SCHEMBL2635294 | 0.81 | HSD17B10 (0.64) | HSD17B10KDM4EALDH1A1SLC6A9 | |
| Tetraxetan SCHEMBL18018 | 0.81 | HSD17B10 (0.64) | HSD17B10KDM4EALDH1A1SLC6A9 | |
| SCHEMBL321989 | 0.81 | HSD17B10 (0.64) | HSD17B10KDM4EALDH1A1SLC6A9 | |
| SCHEMBL6848102 | 0.81 | HSD17B10 (0.64) | HSD17B10KDM4EALDH1A1SLC6A9 | |
| SCHEMBL3660521 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190144284-A1 | FUNCTIONALISED GRAPHENE | BLANFORD, Christopher (GB) | 2019-05-16 | — | — | US | disclosed |
| US-10173898-B2 | Functionalized graphene | BLANFORD, Christopher (GB) | 2019-01-08 | — | — | US | disclosed |
| US-20170081195-A1 | FUNCTIONALISED GRAPHENE | WEHNER, MIRJA (DE) | 2017-03-23 | — | — | US | disclosed |
| US-20170081195-A1 | FUNCTIONALISED GRAPHENE | WEHNER, MIRJA (DE) | 2017-03-23 | — | — | US | disclosed |
| WO-2015170124-A1 | FUNCTIONALISED GRAPHENE | THE UNIVERSITY OF MANCHESTER (GB) | 2015-11-12 | — | — | WO | disclosed |
| US-5919431-A | 1,4,7,10-tetraazacyclododecane derivatives, their use, pharmaceutical agents containing these compounds and process for their production | SCHERING AKTIENGESELLSCHAFT (DE) | 1999-07-06 | — | — | US | disclosed |
| EP-0730586-A1 | 1,4,7,10-TETRAAZACYCLODODECANE DERIVATIVES, THEIR USE, PHARMACEUTICALS CONTAINING THEM AND PROCESS FOR THEIR PRODUCTION | SCHERING AKTIENGESELLSCHAFT (DE) | 1996-09-11 | — | — | EP | disclosed |
| WO-1995014678-A1 | 1,4,7,10-TETRAAZACYCLODODECANE DERIVATIVES, THEIR USE, PHARMACEUTICALS CONTAINING THEM AND PROCESS FOR THEIR PRODUCTION | SCHERING AKTIENGESELLSCHAFT (DE) | 1995-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190144284-A1 | FUNCTIONALISED GRAPHENE | GIGYF2, GLMN, COXFA4 | HSD17B10 2194/4885NPC1 4433/4885RAB9A 2472/4885 |
| US-20170081195-A1 | FUNCTIONALISED GRAPHENE | GIGYF2, GLMN, COXFA4 | HSD17B10 2194/4885NPC1 4433/4885RAB9A 2472/4885 |
| US-10173898-B2 | Functionalized graphene | GIGYF2, GLMN, GYPA | HSD17B10 2473/4885NPC1 4420/4885RAB9A 2249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.